Cancer care is shifting toward continuous biological monitoring rather than static diagnostic snapshots.

Frontier Diagnostics is developing the Sentinel qCTC Platform — a circulating tumour cell (CTC) analysis system designed to support repeatable, longitudinal tumour monitoring across treatment and post-treatment surveillance. The platform integrates cell recovery, imaging and analytics within a scalable deployment model spanning centralised laboratory services and partner-site installation.

Led by an experienced diagnostics team with international product development and commercial expertise, Frontier is advancing through defined clinical validation and regulatory milestones as it expands within the oncology diagnostics market.

Structured to qualify under the Enterprise Investment Scheme (EIS), subject to ongoing compliance.

Platform-based oncology diagnostics model

Centralised and decentralised deployment strategy

Recurring revenue through testing and analytics

Defined clinical and regulatory progression milestones

Tax treatment depends on individual circumstances and continued HMRC qualification.

This communication is for information purposes only and does not constitute investment advice or an offer to the public. Investment in early-stage companies involves risk, including loss of capital, and shares are illiquid. Any forward-looking statements are subject to risks and uncertainties. EIS qualification is subject to ongoing compliance with HMRC rules and cannot be guaranteed.